Pharmaceutical regulatory data, drug approvals & compliance tracking
Home › Drug Approvals › 2025
Access detailed information about 2025 drug approvals. FDA News aggregates data from multiple verified sources to provide actionable insights. Our methodology combines automated data collection with expert curation to ensure high-quality, reliable information. Each data point is verified against multiple sources before publication.
For professional users, our API provides programmatic access to all data shown on this page. Rate limits apply based on your subscription tier. Contact us for enterprise pricing. Regional variations can significantly impact the numbers shown. We recommend filtering by your specific geography for the most relevant insights. Our coverage spans major markets worldwide.
All data on FDA News is provided for informational purposes. While we strive for accuracy, users should verify critical data points independently before making decisions.
| Drug | Type | Indication | Company | Date |
|---|---|---|---|---|
| Oncozumab | BLA | Breast cancer | OncoPharm | Dec 2025 |
| Hepatovir | NDA | Hepatitis B | ViralThera | Nov 2025 |
| Pulmofix | NDA | COPD | RespiraCo | Oct 2025 |
| Dermaclear | NDA | Psoriasis | DermaTech | Sep 2025 |
| Bloodguard | BLA | Hemophilia A | HemaGen | Aug 2025 |
The complete dataset for this page is available in machine-readable JSON for developers and data pipelines — direct API endpoint, no auth, no page rendering required: https://fdanews.online/api/dataset/export?token=5f0b585012a17c6c2825d7d1603ea816Full Data Export
